| DIRECT COMPETITOR COMPARISON | |
| ADLR | ENDP | PFE | PGNX | Industry | | Market Cap: | 69.04M | 2.65B | 147.27B | 124.44M | 163.44M | | Employees: | 128 | 1,216 | 81,800 | 244 | 95 | | Qtrly Rev Growth (yoy): | 10.10% | 14.00% | -2.90% | -69.00% | 20.50% | | Revenue (ttm): | 32.82M | 1.42B | 45.82B | 38.62M | 46.74M | | Gross Margin (ttm): | -46.70% | 75.15% | 86.61% | -43.09% | 68.58% | | EBITDA (ttm): | -50.14M | 461.38M | 21.31B | -42.70M | -7.12M | | Oper Margins (ttm): | -157.95% | 27.58% | 37.42% | -123.04% | 2.25% | | Net Income (ttm): | -56.16M | 197.58M | 8.09B | -44.57M | N/A | | EPS (ttm): | -1.213 | 1.685 | 1.204 | -1.466 | -0.17 | | P/E (ttm): | N/A | 13.41 | 15.16 | N/A | 18.38 | | PEG (5 yr expected): | N/A | 0.86 | 5.88 | N/A | 1.04 | | P/S (ttm): | 2.12 | 1.89 | 3.27 | 3.34 | 4.37 |
|
| ENDP = Endo Pharmaceuticals Holdings Inc. | | PFE = Pfizer Inc. | | PGNX = Progenics Pharmaceuticals Inc. | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | PFE | | The fall of the world's best-selling drug
Fri 7:30pm -
at FT.com | | • | PFE | | This Week's 5 Dumbest Stock Moves
Fri 1:01pm -
at Motley Fool | | • | PFE | | Discover This Secret Weapon for Your Portfolio
Fri 10:12am -
at Motley Fool | | • | PFE | | 3 China Profit Plays
Fri 9:29am -
at Motley Fool | | • | PFE | | Bayer not ruling out large acquisitions - CEO
Fri 6:03am -
at Reuters | | • | ENDP | | Prospecting for Stocks: Novartis
Wed, Nov 25 -
at Motley Fool | | • | ENDP | | 12 Companies With Ironclad Balance Sheets
Wed, Nov 25 -
at Motley Fool | | • | ENDP | | Which Drug Companies Could Be Private-Equity Targets?
Mon, Nov 23 -
at The Wall Street Journal Online | | • | PGNX | | A Possible New Indication for Progenix's Relistor Could Revive Its Fortunes
Fri, Nov 20 -
at Seeking Alpha | | • | PGNX | | Pain drug morphine may accelerate cancer growth
Wed, Nov 18 -
at Reuters | | • | PGNX | | 4-Star Stocks on the Upswing
Wed, Nov 18 -
at Motley Fool | | • | PGNX | | Progenics: Are the Prospects That Bad?
Mon, Nov 16 -
at Seeking Alpha | | • | ENDP | | ENDO PHARMACEUTICALS HOLDINGS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Fri, Nov 13 -
EDGAR Online | | • | PGNX | | PROGENICS PHARMACEUTICALS INC Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | ENDP | | Endo paying $23M to settle patent dispute with LecTec
Thu, Nov 12 -
at bizjournals.com | | • | ENDP | | UPDATE - Endo and LecTec settle patent dispute
Wed, Nov 11 -
at Reuters | | • | PGNX | | PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition
Mon, Nov 9 -
EDGAR Online | | • | PGNX | | CORRECTING and REPLACING Progenics Announces Third Quarter 2009 Financial Results
Mon, Nov 9 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
